Company news
Solid Biosciences Inc. (NASDAQ:SLDB) news
Solid Biosciences Inc. news releases on 6ix. Latest, Jan 16, 2024: Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene…
Press releases — page 2
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
January 15, 2024
Solid Biosciences Announces $109 Million Private Placement
January 7, 2024
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
December 6, 2023
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
November 13, 2023
Solid Biosciences Provides Third Quarter Business Update and Financial Results
November 7, 2023
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
October 1, 2023
Solid Biosciences Provides Second Quarter Business Update and Financial Results
August 13, 2023
Solid Biosciences Provides First Quarter Business Update and Financial Results
May 10, 2023
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
March 22, 2023
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
January 10, 2023
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
January 8, 2023
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
January 8, 2023
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
December 4, 2022
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
November 30, 2022
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
November 9, 2022
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
October 26, 2022
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
September 29, 2022
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
August 10, 2022
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
June 1, 2022
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
April 26, 2022
Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
March 13, 2022
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
January 9, 2022
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources
January 3, 2022
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
November 2, 2021
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
October 3, 2021
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 28, 2021
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 22, 2021
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 19, 2021
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance
August 18, 2021
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
August 15, 2021
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
July 1, 2021
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
June 30, 2021
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
June 6, 2021
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
June 6, 2021
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results
May 13, 2021
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
March 22, 2021
Solid Biosciences Announces Pricing of Public Offering of Common Stock
March 17, 2021
Solid Biosciences Announces Proposed Public Offering of Common Stock
March 16, 2021
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
March 14, 2021
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
March 3, 2021
Solid Biosciences Announces Appointments to Management Team and Board of Directors
March 3, 2021
Solid Biosciences Announces $90 Million Private Placement
December 10, 2020
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
September 30, 2020
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold
July 23, 2020
Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors
June 17, 2020
Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020
May 21, 2020
Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD
May 6, 2020
Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors
April 15, 2020
Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 11, 2020